Xeris Biopharma Holdings, Inc.
Precipitation resistant small molecule drug formulations

Last updated:

Abstract:

Embodiments of the invention are directed to formulations that provide a solution to the problem of small molecule (e.g., diazepam) precipitation at the injection site when administered as a highly-concentrated formulation. In certain aspects the formulations include at least one surfactant in a non-aqueous formulation, which prevents small molecule precipitation and improves the bioavailability of the drug by enhancing absorption into the systemic circulation.

Status:
Grant
Type:

Utility

Filling date:

31 May 2018

Issue date:

1 Jun 2021